Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Carclo Plc LSE:CAR London Ordinary Share GB0001751915 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.70p +2.22% 32.20p 31.50p 32.90p 31.60p 31.40p 31.40p 57,138 16:35:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 146.2 8.2 11.6 2.8 23.60

Carclo Share Discussion Threads

Showing 17801 to 17824 of 18075 messages
Chat Pages: 723  722  721  720  719  718  717  716  715  714  713  712  Older
DateSubjectAuthorDiscuss
13/8/2018
12:41
The group Finance Director buys 20.45k shares, is she insane!
ansc
13/8/2018
10:52
News - this extract sounds reassuring: "Carclo has won significant new business in the healthcare, medical diagnostics and eyecare fields during 2017/18" Http://www.carclo-ctp.co.uk/media-centre/press-releases/25-07-2018.aspx "Carclo announces Compamed attendance 25 Jul 2018 London (UK), 25 July 2018: Carclo Technical Plastics announces that it will be exhibiting at the Compamed exhibition in Dusseldorf, Germany, 12-15 November 2018, on stand no 8AS19. Carclo has recently expanded its medical operations in its US, UK, Czech Republic, China and India facilities as it continues its strategy of increasing its contract manufacturing business globally. Underpinned by its EN13485 accreditation, Carclo has won significant new business in the healthcare, medical diagnostics and eyecare fields during 2017/18. Commenting, Divisional Chief Executive Officer Robert Stutzman stated “Carclo Technical Plastics has aggressive plans to continue developing our medical business, supported by Carclo’s engineering skills, global footprint and financial stability. Compamed, co-located with the renowned Medica tradeshow, is one of our prime marketing activities and we invite all customers and prospective customers to meet with us during the week.” Carclo’s clients range from globally-located divisions of major healthcare corporations to start-up companies who are developing products for the innovative yet highly-regulated medical industry. Products include medical and surgical disposables, drug delivery devices, reagent packs and diagnostic devices and ophthalmic equipment and consumables. Carclo Technical Plastics currently has manufacturing facilities in Eastern and Western USA; London, UK; Brno, Czech Republic; Shanghai, China, and Bangalore, India. The business increasingly adds value to its customers by assembling and packaging finished devices for the medical sector."
rivaldo
10/8/2018
12:45
1gw agree again. And they have some handy losses to use up :)The new chairman should indeed bring some focus coupled with the crash course in valuation. Senior I assume was diversified but whether to the zero synergy extent of little sub scale Carclo I don't know.
queeny2
10/8/2018
08:37
Axxion continue to buy per yesterday's RNS - now up to 4.66m shares: Http://uk.advfn.com/stock-market/london/carclo-CAR/share-news/Axxion-S-A-Form-8-3-Carclo-plc/78039218
rivaldo
09/8/2018
22:05
1gw:-I have now had a look at p21 Thanks - - Initial reaction is that very similar boiler plate to many risk managment statements from other companies with international business - CAR specific points have been slotted in - 1/3rd of UK situs revenue could be at risk from Brexit but no indication as to whether this is at risk from tariffs or quality certification. Again while 2/3rds of UK revenue is from the UK no idication as to what proportion of their coustomers revenue could be at risk and hence a knock-on risk- Overall impression of the risk statement is that it is very much a box ticking exercise - all risk factors covered but shareholders rather left in the dark in terms of quantification. I suspect the Board are as much in the dark as most economists, politicians and even the Bank of England !!- Conclusion - Would not pay more for stock that a p/e of 8 to 9 - Possibly less given the pension liabilities.
pugugly
09/8/2018
20:07
One thing the Consort experience should have done is give the board a much better insight into how their competitors/peers view and value Carclo. This should include a reasonable understanding now of how a CTP competitor/peer would assess Wipac, and perhaps also how a Wipac competitor/peer might assess Wipac (assuming they did sound out one or two, or at least got their advisors to do some serious analysis on the subject). I wonder if the board might now push the executive to re-examine the logic for keeping Wipac and CTP together (if there is any beyond having a bigger business to run). Would shareholders ultimately be better served by splitting the businesses as this would make it easier to achieve fair value for each one? Either spin off one if the two are viable as independent businesses or simply run a sale process for the smaller one - especially if they have already kicked off some work on this as part of the defence preparations.
1gw
09/8/2018
19:55
Carclo's own spin on the issue (Political uncertainty including Brexit) is on page 21 of the AR.
1gw
09/8/2018
18:37
Worth a check of revenue segmentation in 2018 accounts - see page 79 Only £40M in UK £45m North America £60M rest of world (probably imo mainly EU) I have not been able to find the production breakdown in these areas (it may be there but 116 pages!!) So potentially at high risk from Brexit and US tariffs from Trump's hissie fits. Or am I being paranoid?
pugugly
09/8/2018
17:48
1gw yes agree
queeny2
09/8/2018
17:39
You may be right about a white knight struggling to find more value than Consort but to my mind Consort was always an unlikely acquirer with 100% of their business in healthcare and the Carclo portfolio of product much more diverse with their key growth market in automotive. I think we may yet be surprised at the attraction of this business if they can manage their operating margins more effectively which would appear work in progress. The pension deficit should look after itself in the medium term.
remslie
09/8/2018
11:15
Speculation of course, but my guess would be that Consort overstretched themselves with the 13th July offer in order to get talking to Carclo. Carclo had said they would be prepared to discuss a proposal that they would be minded to recommend to shareholders so given they were discussing the 13th July proposal I think that must have been worth around 130p or more (given the 116p proposal was rejected out of hand). The Consort share price had fallen a bit between their proposals, so the "cost" to them in Consort shares would have gone up more than the headline price difference in the proposals. With Consort now presumably having seen the books, I think the Consort walk-away is telling us that Consort don't believe they can make a reasonable return on their investment in Carclo at their 13th July proposal level. I don't think the strategic benefits would have changed so I think that's down to the perceived value of synergies, maybe the resale value of Wipac and maybe also further thought about the pension deficit. Given the synergies aren't available to Carclo on a standalone basis, that would seem to put a medium-term cap on the value of Carclo, unless they can achieve significantly more value from Wipac than was implicit in the Consort proposal. Equally, for reasons discussed on this board before, it's quite difficult to see a white knight seeing much more value in Carclo than Consort could. Since we don't know the level of the Consort revised proposal, it's difficult to say what that cap is. But we can fall back perhaps on the 2nd July Carclo statement that the 116p proposal "in no way reflected the fundamental value of the Company". So now I imagine institutional holders will be putting pressure on the Carclo board to take actions in the near term which get the share price closer to that fundamental value that the board claim to see. It's good to see that Axxion continued to buy post deal-collapse, buying on both the 7th and yesterday. It would be nice to see other shareholders and indeed the board themselves showing confidence in the board's valuation and adding to their holdings while the shareprice remains below 116p.
1gw
08/8/2018
14:56
I now understand. I'm new here and trying to learn. n.b. yes they were 8.5s!
thelongterm
08/8/2018
14:05
Peel Hunt are Carclo brokers and as such had to report all agency business they transacted during the Offer Period. Normal stuff.
queeny2
08/8/2018
13:45
Those were 8.5s weren't they? ie buying and selling as an intermediary on behalf of various clients.
1gw
08/8/2018
13:23
Now at 91p it is still higher than the price of 80.28p on the 29th June just before the announcement of the approach! Also I don't understand Peal Hunt (who reported a Consort connection) in their 8.3 filings they kept buying AND selling, making/losing small sums, why? I could understand day traders doing so.
thelongterm
08/8/2018
12:45
Today's RNS shows Axxion are still buying - they now have 4.6m shares, 170,000 shares more than the previous day.... Http://uk.advfn.com/stock-market/london/carclo-CAR/share-news/Axxion-S-A-Form-8-3-Carclo-plc/78029487
rivaldo
07/8/2018
18:58
oh, i see at top of page ... "The latest forecasts are (as at 11th June 2018): - to Mar'20 - 12.45p EPS (consensus forecast from 2 analysts) - to Mar'19 - 11.17p EPS (consensus forecast from 3 analysts)"
queeny2
07/8/2018
18:57
rivaldo can you remind us of broker forecasts, and if any updates from Peel Hunt following the end of the bid period? thanks
queeny2
07/8/2018
13:41
Poor management of this company continues.
overmars
07/8/2018
12:59
Without the onerous pensions deficit I suspect the whole saga would have played out very differently. TOO MUCH DEBT
bigtbigt
07/8/2018
10:43
Guess I was right (again!!!)
gordongekko4
07/8/2018
10:30
...so on the other hand....:o)) From our POV it's just speculation as to whether Consort were trying it on cheaply from CAR's perspective, or whether Consort were unhappy with the books or prospects, or whatever. We'll never know. CAR's statement that they are "highly" confident going forward is unusually strong. It'll be interesting to see whether CAR's primarily institutional shareholder base give any indications in public as to their happiness or unhappiness with the whole bid situation etc.
rivaldo
07/8/2018
10:09
"The Board of Carclo remains highly confident in the Group's prospects and standalone strategy." economical
queeny2
07/8/2018
10:02
Remslie - Or another possible scenario: they are engaged in selling Wipac and the resulting balance sheet would make the maximum price that Concord have in mind look unrealistic...?
pldazzle
Chat Pages: 723  722  721  720  719  718  717  716  715  714  713  712  Older
Your Recent History
LSE
CAR
Carclo
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190525 23:13:48